|Bid||20.00 x 900|
|Ask||23.30 x 1100|
|Day's Range||19.50 - 22.68|
|52 Week Range||16.00 - 22.68|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Gossamer Bio, Inc. , a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of
The executive chairman of Gossamer Bio (NASDAQ: GOSS) has a lofty goal for the company: Be the next version of Genentech, the biotechnology giant that is now a subsidiary of Roche (OTCPK: RHHBY). The odds are high, but Faheem Hasnain's track record suggests he may have assembled just the team to make that dream a reality. If the company comes anywhere near being the next Genentech, the share price will prove to be the biggest bargain since the purchase of Alaska.
Gossamer Bio, Inc. (GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced the closing of its previously announced initial public offering of 19,837,500 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase 2,587,500 additional shares, at a price to the public of $16.00 per share. Including the option exercise, the aggregate gross proceeds to Gossamer Bio from the offering, before deducting the underwriting discounts and commissions and other offering expenses, were $317.4 million. BofA Merrill Lynch, SVB Leerink, Barclays and Evercore ISI acted as joint book-running managers for the offering.
The IPO market is expected to show another uptick in volume this week as six initial public offerings are set to price and raise $882.6 million in proceeds. It follows three IPOs last week.
Inc. made their stock market debuts Friday as a new year of initial public offerings got under way in earnest for biotechnology companies encouraged by last year’s parade of new issues. Inc., another biotech concern, staged its own IPO. More biotech offerings are scheduled for next week, including new issues from TCR2 Therapeutics Inc. and Stealth BioTherapeutics Corp.
Shares of Gossamer Bio, Inc. opened at $19 Friday on the Nasdaq , or 19% above its initial public offering price of $16, before falling back to $16.50, or 3% above the initial IPO price. The first trade crossed at 11:22am Eastern for 762,609 shares. The IPO priced on Thursday evening, with the company selling 17.25 million shares to raise $276 million. The iShares Nasdaq Biotechnology ETF has gained 10.7% in the year to date, while the S&P 500 is up 7.2%.
Gossamer Bio, Inc. (GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced the pricing of its initial public offering of 17,250,000 shares of common stock at a public offering price of $16.00 per share. The shares are expected to begin trading on the Nasdaq Global Select Market on February 8, 2019 under the ticker symbol “GOSS.” All of the shares are being offered by Gossamer Bio. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Gossamer Bio, are expected to be $276.0 million.
For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . IPO dates below are expected but not confirmed. Alector, Inc. (ALEC) will issue 9.25 million shares between $18 and $20 ...